BioCardia, which is developing gene therapies for cardiovascular diseases, announced terms for its IPO on Monday.
The San Carlos, CA-based company plans to raise $50 million by offering 3.85 million shares at a price range of $12 to $14. At the midpoint of the proposed range, BioCardia would command a fully diluted market value of $154 million.
BioCardia, which was founded in 2002, plans to list on the NASDAQ under the symbol BCDA. Cantor Fitzgerald, Roth Capital and Maxim Group LLC are the joint bookrunners on the deal.
The article The heart of gene therapy: BioCardia sets terms for $50 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.